Oral androgen
Fluoxymesterone (Halotestin)
Fluoxymesterone (Halotestin) after one dose: 50% at ~9.2 h, 25% at 18.4 h, 12.5% at 27.6 h.
Drawn from the half-life in the app's model, ~9.2 h. The model's figures
- Compound
- Fluoxymesterone (Halotestin)
- Symbol
- HAL
- Family
- Other steroids
- Parts
- 14
- References
- 15
- Checked
- Last reviewed . Sources are listed below.
Overview
Halotestin is the brand name of fluoxymesterone tablets from Pharmacia and Upjohn Company, whose label states that the tablets "contain fluoxymesterone, an androgenic hormone".1 The label lists two sets of indications: in the male, "replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone" (primary hypogonadism, hypogonadotropic hypogonadism and delayed puberty), and in the female, "palliation of androgen-responsive recurrent mammary cancer" in women who are more than one year but less than five years postmenopausal or who have a hormone-dependent tumor shown by previous beneficial response to castration.1 The label also states: "This drug has not been shown to be safe and effective for the enhancement of athletic performance".1
The WADA 2026 Prohibited List names fluoxymesterone among the anabolic androgenic steroids prohibited at all times.2 The label gives a half-life of approximately 9.2 hours after oral administration, the same figure as the app's, while a 1985 study of 6 people reported a harmonic mean half-life of 2.0 hours.1,3
How it works
What the label says about androgens
The label's clinical pharmacology section describes androgens as a class: "Androgens have been reported to increase protein anabolism and decrease protein catabolism".1 It adds that "Nitrogen balance is improved only when there is sufficient intake of calories and protein".1 It also states that "During exogenous administration of androgens, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH)".1 Ingle and colleagues, Breast Cancer Research, 2025, describe fluoxymesterone as "an AR-agonist" (androgen receptor).4
In people
Spitz and colleagues, Hormone and Metabolic Research, 1984, studied 27 patients with primary testicular failure and called mesterolone and fluoxymesterone "non aromatizable androgens"; nine received mesterolone and the remaining subjects fluoxymesterone, which was given as 5 mg daily for 4 weeks and then 10 mg daily for 2 weeks.5 During fluoxymesterone administration there was "a reduction in testosterone, gonadotropins and LH response to LHRH", a reduction in the peak and integrated TSH response to TRH, a reduction in thyroid binding globulin, an unaltered free T4 index and unaltered prolactin levels.5 The PubMed record is cut off at 250 words.5
In cells
Fürstenberger and colleagues, University of Basel, Toxicological Sciences, 2012, tested recombinant human 11β-hydroxysteroid dehydrogenase 2 (11β-HSD2) and reported that "fluoxymesterone was a potent inhibitor", with a half-maximal inhibitory concentration of 60 to 100 nM in cell lysates, 160 nM in intact SW-620 cells and 530 nM in MCF-7 cells.6 In rat kidney microsomes and in cells expressing mouse 11β-HSD2 the inhibition by the steroids tested was "much weaker", and the authors report that human 11β-HSD2 metabolized fluoxymesterone to 11-oxofluoxymesterone.6 They observed "No direct modulation of mineralocorticoid receptor (MR) function", and wrote that the inhibition "may cause cortisol-induced MR activation", which is the authors' proposal from enzyme and cell work, not a result in people.6 The PubMed record lists no funding statement and no competing interests for that study.6
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~9.2 h
- Bioavailability
- 80%
- Typical dose
- 5–30 mg/day
- Route
- Oral
- Time to peak
- ~2 h
The label states: "The half-life of fluoxymesterone after oral administration is approximately 9.2 hours".1 Capponi and colleagues, Journal of Pharmaceutical Sciences, 1985, reported a harmonic mean half-life of 2.0 hours for tablets given buccally or orally, without a split by route; neither the label nor that record gives a reason for the difference.3
| Parameter | App's figure | Source figures |
|---|---|---|
| Half-life | ~9.2 hours | Label: approximately 9.2 hours after oral administration.1 Capponi and colleagues, 1985: harmonic mean 2.0 hours in 6 subjects after a 10 mg tablet given buccally or orally; the record does not split it by route.3 |
| Bioavailability | 80% | The label gives no oral bioavailability figure. Capponi and colleagues report that mean Cmax and AUC after an oral tablet were 80 and 76% of the mean values after a buccal tablet, a comparison between two routes in 6 subjects.3 |
| Time to peak | ~2 hours | Capponi and colleagues: tmax 1 to 2 hours, with Cmax from 40 to 150 ng/mL after a 10 mg tablet given buccally or orally; the record does not split these by route.3 The label gives no time to peak. |
| Route | Oral | Label tablets are for oral administration; the 1985 study compared an oral with a buccal tablet.1,3 |
The chart below is an illustration from the app's half-life of 9.2 hours and time to peak of about 2 hours with the dosing intervals that trials in the next section report. It is a model, not measured concentrations, and the 2.0 hour half-life from Capponi and colleagues is not used in it.
Deeper analysis: Capponi and colleagues, 1985
The paper describes a liquid chromatography assay for fluoxymesterone in human serum and applies it to "a bioavailability study in which six subjects each received two treatments of 10-mg fluoxymesterone tablets in a Latin-square crossover study".3 Cmax values ranged from 40 to 150 ng/mL, tmax values were 1 to 2 hours, and less than 8% of the AUC was extrapolated.3 The PubMed record lists no funding, no affiliations and no competing interests, and states no limitations; the study is labelled "preliminary" in its title.3
Human studies
A search of PubMed for "fluoxymesterone[tiab]" on 16 November 2026 returned 281 records, 27 of them with the publication type randomized controlled trial. The table lists eight studies in people with cancer, delayed growth or anaemia; it is a selection, and the other records are not summarised here.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Ingle and colleagues, 19889 | Randomized trial, tamoxifen alone against tamoxifen plus fluoxymesterone | Postmenopausal women with metastatic breast cancer; 119 per arm | 10 mg orally twice daily of both drugs; length not stated in the record | Objective response 42% (50 of 119) on tamoxifen alone against 53% (63 of 119) on the combination, one-sided P = .05; median time to progression 199 days on tamoxifen alone against 350 days on the combination, one-sided P = .07; survival similar; more androgenic side effects on the combination |
| Ingle and colleagues, 199110 | Updated analysis of the same trial | Postmenopausal women with metastatic breast cancer; 119 per arm | 10 mg orally twice daily of both drugs | Objective response 42% against 54% (64 of 119), two-sided P = 0.07; median time to progression 6.5 months (alone) against 11.6 months (combination), P = 0.03; duration of response and survival similar between arms; in a subgroup of 97 patients (ER of 10 or greater, age 65 or older) the authors reported a survival advantage for the combination (Cox model, P = 0.05) and wrote that the data require confirmation in a prospective randomized trial |
| Ingle and colleagues, 20067 | Randomized trial, adjuvant tamoxifen alone against tamoxifen plus fluoxymesterone | 541 eligible postmenopausal women with resected ER-positive breast cancer | Tamoxifen 20 mg a day for 5 years; fluoxymesterone 10 mg twice daily for 1 year; median follow-up of patients still alive 11.4 years | No significant difference in relapse-free or overall survival; adjusted hazard ratio (combination over tamoxifen alone) 0.84 (95% CI 0.64 to 1.10) for relapse or death without relapse, 0.89 (0.67 to 1.18) for death; more virilization with fluoxymesterone |
| Kono and colleagues, 201611 | Retrospective review of patients treated from 2000 to 2014 | 103 patients with hormone receptor-positive metastatic breast cancer after a median of 3 (range 1 to 10) hormonal therapies | Dose and length not stated in the record | 33 stopped before progression because of physician decision or adverse events, including toxicity in 14; of 70 others, 2 complete responses (3%), 7 partial (10%), 21 stable disease for 6 months or more (30%); clinical benefit rate 43%; median progression-free survival 3.9 months (95% CI 3.2 to 5.3); AR expression not significantly associated with survival (39 patients with archived tumour slides) |
| Loprinzi and colleagues, 199912 | Randomized phase III, three arms | Patients with cancer anorexia/cachexia; arm sizes not in the record | Fluoxymesterone 10 mg twice daily against megestrol acetate 800 mg daily or dexamethasone 0.75 mg four times daily; monthly follow-up | Significantly less appetite enhancement with fluoxymesterone, which "did not have a favorable toxicity profile" |
| Strickland, 19938 | Prospective study, untreated group followed for height prediction | 82 boys (71 constitutional delay of growth and puberty, 11 genetic short stature); 34 untreated | 2.5 mg orally daily for 6 to 60 months | 1.7- to 2.5-fold rise in growth velocity; final height 6.1 +/- 3.5 cm (Greulich-Pyle and Bayley-Pinneau) and 5.4 +/- 3.2 cm (sexual maturity index) above pretreatment predictions; no adverse androgenic effects observed |
| Brubaker and colleagues, 198213 | Randomized, fluoxymesterone with transfusions against transfusions alone | 29 patients with anaemia from myelofibrosis (16) or other myeloproliferative disorders (13); 24 evaluable | 30 mg a day orally; length not stated in the record | 4 of 14 (29%) responded well to fluoxymesterone against no good responders and 1 partial responder among 10 on transfusions alone; all responders had myelofibrosis; no significant survival difference |
| French Cooperative Group, 198614 | Randomized, two androgens at two doses, and four androgens at high dose | 110 patients (fluoxymesterone or norethandrolone, high or low dose) and 125 others (four androgens, high dose) with aplastic anaemia | 1 mg/kg/day (high) or 0.2 mg/kg/day (low); 18 months named in the conclusion | Efficacy of high-dose androgens in less severe cases; among the four androgens, fluoxymesterone the most efficient and stanozolol the least |
Deeper analysis: tamoxifen with or without fluoxymesterone, metastatic breast cancer
Ingle and colleagues at the Mayo Clinic, Journal of Clinical Oncology, 1988, randomized postmenopausal women with metastatic breast cancer to tamoxifen alone or with fluoxymesterone, 10 mg twice daily of each, with 119 women per arm.9 Time to progression distributions were better for the combination (median 350 against 199 days), but the log rank test "only approached statistical significance" (one-sided P = .07), and "Duration of response and survival distributions were similar between the two treatment arms".9 The authors concluded that the advantages in response rate and time to progression "probably represent a biological effect" but are "not of sufficient magnitude to justify the routine clinical use of this combination", given the lack of survival advantage and the side effects.9 The PubMed records for the 1982, 1988 and 1991 papers list National Institutes of Health support (publication type Research Support, U.S. Gov't, P.H.S.) and no competing-interest statement.13,9,10
Deeper analysis: NCCTG 89-30-52, adjuvant tamoxifen with or without fluoxymesterone
Ingle and colleagues, Mayo Clinic, Breast Cancer Research and Treatment, 2006, tested whether the earlier finding in metastatic disease held in women with resected, estrogen receptor-positive breast cancer.7 In 541 eligible women entered from 1991 to 1995, relapse-free survival (the primary endpoint) and overall survival did not differ significantly, with adjusted hazard ratios (combination over tamoxifen alone) of 0.84 (95% CI 0.64 to 1.10) for relapse or death without relapse and 0.89 (95% CI 0.67 to 1.18) for death after a median follow-up of patients still alive of 11.4 years.7 The authors wrote that the trial "did not demonstrate superiority of Tam plus Flu over Tam alone", and "As expected there was more virilization in women who received Flu".7 The PubMed record lists National Institutes of Health grants (publication type Research Support, N.I.H., Extramural), no competing-interest statement and no stated limitations.7 In the 2025 tissue analysis of the same trial, 301 of 514 patients (59%) had sufficient tissue, and 11 of them with poor or moderate ER staining were excluded (the 2025 record states 514 patients and the 2006 paper reports 541 eligible).4 Within the AR-enriched patients, the cumulative incidence of relapse-free survival events showed an advantage for the combination that reached significance (Gray's test p = 0.0472), a subgroup result, and the authors wrote that an AR-agonist "may be of value in AR-enriched, ER-enriched breast cancers" and proposed study in future trials.4 The PubMed record lists the Nan Sawyer Breast Cancer Fund, the George M. Eisenberg Foundation for Charities, the Breast Cancer Research Foundation and National Institutes of Health grants.4 Its competing-interest statement says one author is a co-founder and stockholder in OneOme, LLC, and another reports personal and consulting fees and grant funding to the Mayo Clinic from several companies, while "The other authors declare no financial interests".4
Deeper analysis: megestrol acetate, dexamethasone and fluoxymesterone in cancer anorexia and cachexia
Loprinzi and colleagues, Mayo Clinic, Journal of Clinical Oncology, 1999, randomized patients with cancer anorexia or cachexia to dexamethasone 0.75 mg four times daily, megestrol acetate 800 mg daily or fluoxymesterone 10 mg twice daily.12 They measured weight changes, appetite and drug toxicity at monthly intervals.12 "Fluoxymesterone resulted in significantly less appetite enhancement and did not have a favorable toxicity profile".12 Megestrol acetate and dexamethasone caused "a similar degree of appetite enhancement", dexamethasone had a higher rate of discontinuation for toxicity or refusal than megestrol acetate (36% v 25%; P = .03), and megestrol acetate had a higher rate of deep venous thrombosis than dexamethasone (5% v 1%; P = .06, not below .05); the record gives no such rates for fluoxymesterone.12 The authors concluded that fluoxymesterone "clearly seems to be an inferior choice" for cancer anorexia and cachexia.12 The PubMed record lists National Institutes of Health grants (publication type Research Support, U.S. Gov't, P.H.S.), no competing-interest statement, no arm sizes and no stated limitations.12
Deeper analysis: Strickland, 1993, boys with delayed growth
Strickland, Spartanburg Regional Medical Center, Pediatrics, 1993, followed 82 short boys given 2.5 mg of fluoxymesterone daily by mouth for 6 to 60 months between 1973 and 1984, with final height assessed from 1989 to 1991.8 The untreated group of 34 boys was followed "to assess the accuracy" of the height prediction methods, so the record describes no randomized comparison of final height.8 The author reported that "No adverse androgenic effects (or undue acceleration of puberty) were observed".8 The label states that "Androgens can accelerate bone maturation without producing compensatory gain in linear growth".1 The PubMed record lists no funding or competing interests for the paper.8
Doses reported in studies and on the label
The app's typical dose is 5–30 mg/day. The label states that "a daily dose of 5 to 20 mg will suffice in the majority of patients" for complete replacement in the hypogonadal male, and gives 10 to 40 mg a day for palliative therapy in advanced inoperable breast cancer in women.1
| Dose reported | Setting | Source |
|---|---|---|
| Total daily oral dose singly or in divided (three or four) doses; the label also states that, because of its short action, fluoxymesterone is to be given in divided rather than single daily doses to ensure more stable blood levels | Label dosage statement | Label1 |
| 5 to 20 mg a day | Complete replacement in the hypogonadal male | Label1 |
| 10 to 40 mg a day | Palliative therapy, advanced inoperable breast cancer in women | Label1 |
| Therapy limited to four to six months | Delayed puberty | Label1 |
| 5 mg daily for 4 weeks, then 10 mg daily for 2 weeks | Primary testicular failure | Spitz and colleagues, 19845 |
| 1 mg/kg a day or 0.2 mg/kg a day | Aplastic anaemia | French Cooperative Group, 198614 |
Side effects reported
The label's adverse reactions section lists, for males, "Gynecomastia, and excessive frequency and duration of penile erections" and oligospermia at high dosage, and for females amenorrhea, menstrual irregularities, inhibition of gonadotropin secretion and virilization.1 It also lists hirsutism, male pattern of baldness, seborrhea and acne; retention of sodium, chloride, water, potassium, calcium and inorganic phosphates; nausea, cholestatic jaundice and alterations in liver function tests; suppression of clotting factors II, V, VII and X; and polycythemia.1 The label's Warnings state that prolonged use of high doses of androgens, "principally the 17-α alkyl-androgens", "has been associated with development of hepatic adenomas, hepatocellular carcinoma, and peliosis hepatis", and that "Cholestatic hepatitis and jaundice may occur with 17-α-alkyl-androgens".1 It also states that "Hypercalcemia may occur in immobilized patients and in patients with breast cancer" and that "Edema, with or without congestive heart failure, may be a serious complication in patients with pre-existing cardiac, renal or hepatic disease".1 The label's contraindications include males with carcinoma of the breast, males with known or suspected carcinoma of the prostate gland, women known or suspected to be pregnant and patients with serious cardiac, hepatic or renal disease; its pregnancy category is X, and it reports "no reports of acute overdosage with the androgens".1
In the trials above
Androgenic side effects were greater on tamoxifen plus fluoxymesterone in the 1988 trial, and virilization was more frequent in the 2006 adjuvant trial.9,7 In Kono and colleagues' retrospective review, 33 of 103 patients stopped fluoxymesterone before progression because of physician decision or adverse events, including toxicity in 14.11 Strickland reported no adverse androgenic effects in 82 boys given 2.5 mg a day.8 Lo and colleagues, BMJ Case Reports, 2015, described a 28-year-old man with persistent gynaecomastia from fluoxymesterone used for aplastic anaemia before puberty, and wrote that normal hormonal work-ups isolated "the drug as the cause".15
Bloodwork and markers
Sources in this part
The label's laboratory-tests section names liver function tests "Because of the hepatotoxicity associated with the use of 17-alpha-alkylated androgens", hemoglobin and hematocrit levels "(to detect polycythemia)" in long-term administration, and periodic bone age X-ray examinations in prepubertal males.1 It states that "Serum cholesterol may increase during androgen therapy" and that androgens may decrease thyroxine-binding globulin, with free thyroid hormone levels unchanged.1 The app's markers are liver enzymes, lipids and hematocrit.
Regulatory and anti-doping status
Sources in this part
A search of DailyMed on 16 November 2026 for the drug name fluoxymesterone returned 1 label, for Halotestin tablets from Pharmacia and Upjohn Company.1
| Body | Statement | Source |
|---|---|---|
| Label (United States) | "Fluoxymesterone is a controlled substance under the Anabolic Steroids Control Act, and HALOTESTIN Tablets has been assigned to Schedule III." | Label1 |
| Label (United States) | "Rx only"; "Pregnancy Category X" | Label1 |
| WADA Prohibited List 2026 | Fluoxymesterone is listed under S1.1 anabolic androgenic steroids "When administered exogenously"; "Anabolic agents are prohibited." | WADA list2 |
| WADA Prohibited List 2026 | Class S1 is "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)" and "All prohibited substances in this class are non-Specified Substances." | WADA list2 |
| Label, athletic performance | "This drug has not been shown to be safe and effective for the enhancement of athletic performance." The label adds that, because of the potential risk of serious adverse health effects, the drug is not to be used for that purpose. | Label1 |
Storage and handling
Sources in this part
The label lists round, scored tablets of 2 mg (peach), 5 mg (light green) and 10 mg (green), and states: "Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP]".1
What is not known
Of the sources cited, the 1985 study of 6 people reports measured serum concentrations (Cmax 40 to 150 ng/mL after 10 mg, oral and buccal tablets together), and its half-life of 2.0 hours differs from the label's 9.2 hours.3,1 The 1985 study compares an oral with a buccal tablet, and the label gives no oral bioavailability figure.3,1 A search of PubMed on 16 November 2026 for fluoxymesterone with athlete, strength, muscle mass or lean body mass in the title or summary text returned 5 records, and a search with pharmacokinetic or bioavailability returned 1. The label states that fluoxymesterone "has not been tested for mutagenic potential" and that "Impairment of fertility was not tested directly in animal species".1 A 1984 paper calls fluoxymesterone non aromatizable, while the label lists gynecomastia and a 2015 case report attributes persistent gynaecomastia to the drug; the case report states that "the mechanism is not fully clear" for drug-induced gynaecomastia.5,1,15
Frequently asked questions
What is the half-life of Halotestin?
What is Halotestin?
Halotestin is the brand name of fluoxymesterone tablets, which the label calls "an androgenic hormone".1 The label lists replacement therapy in male hypogonadism and delayed puberty, and, in women meeting its postmenopausal or hormone-dependent tumor conditions, palliation of androgen-responsive recurrent mammary cancer.1
Is Halotestin banned by WADA?
Yes, the WADA 2026 Prohibited List names fluoxymesterone under S1.1 anabolic androgenic steroids "When administered exogenously", a class prohibited at all times.2
Is Halotestin a controlled substance?
The label states that fluoxymesterone is a controlled substance under the Anabolic Steroids Control Act and that Halotestin tablets have been assigned to Schedule III.1
Does Halotestin aromatize?
Spitz and colleagues, 1984, called fluoxymesterone one of the "non aromatizable androgens".5 The label lists gynecomastia among male adverse reactions, and a 2015 case report describes persistent gynaecomastia attributed to the drug, noting that "the mechanism is not fully clear" for drug-induced gynaecomastia.1,15
What are the side effects of Halotestin?
The label lists gynecomastia, excessive frequency and duration of penile erections, oligospermia at high dosage, virilization in females, acne, fluid and electrolyte retention and alterations in liver function tests among its adverse reactions.1 Its Warnings state that prolonged use of high doses of 17-α alkyl-androgens "has been associated with development of hepatic adenomas, hepatocellular carcinoma, and peliosis hepatis".1
Is Halotestin approved for athletic performance?
The label states: "This drug has not been shown to be safe and effective for the enhancement of athletic performance".1
What did trials of Halotestin in breast cancer find?
In the 1988 randomized trial of women with metastatic breast cancer, 119 per arm, objective response was 42% on tamoxifen and 53% on tamoxifen plus fluoxymesterone (one-sided P = .05), with similar survival and more androgenic side effects on the combination.9 In the 2006 adjuvant trial of 541 women, relapse-free and overall survival did not differ significantly, and virilization was more frequent with fluoxymesterone.7 The Human studies table also lists a 1991 update of the 1988 trial and a 2016 retrospective review of 103 patients.10,11
What strengths do Halotestin tablets come in?
The label lists Halotestin tablets of 2 mg, 5 mg and 10 mg.1
Guides, tools and comparisons
References
- Pharmacia and Upjohn Company. Halotestin (fluoxymesterone) tablets, prescribing label. DailyMed label page, showing "Information Updated February 6, 2006" and "Aug 21, 2006". DailyMed label
- World Anti-Doping Agency. Prohibited List 2026, in effect from 1 January 2026. WADA list
- Capponi VJ, et al. Liquid chromatographic assay for fluoxymesterone in human serum with application to a preliminary bioavailability study. J Pharm Sci 1985. PMID 4009439
- Ingle JN, et al. Evaluation of the androgen receptor in patients with ERα-positive early breast cancer treated with adjuvant tamoxifen ± fluoxymesterone. Breast Cancer Res 2025. PMID 40108635
- Spitz IM, et al. Effect of non aromatizable androgens on LHRH and TRH responses in primary testicular failure. Horm Metab Res 1984. PMID 6437958
- Fürstenberger C, et al. The anabolic androgenic steroid fluoxymesterone inhibits 11β-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation. Toxicol Sci 2012. PMID 22273746
- Ingle JN, et al. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res Treat 2006. PMID 16538529
- Strickland AL. Long-term results of treatment with low-dose fluoxymesterone in constitutional delay of growth and puberty and in genetic short stature. Pediatrics 1993. PMID 8464656
- Ingle JN, et al. Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer. J Clin Oncol 1988. PMID 3284975
- Ingle JN, et al. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer 1991. PMID 1991261
- Kono M, et al. Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy. Breast Cancer Res Treat 2016. PMID 27663436
- Loprinzi CL, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999. PMID 10506633
- Brubaker LH, et al. Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. Arch Intern Med 1982. PMID 7103635
- French Cooperative Group for the Study of Aplastic and Refractory Anemias. Androgen therapy in aplastic anaemia: a comparative study of high and low-doses and of 4 different androgens. Scand J Haematol 1986. PMID 2872720
- Lo TE, et al. Fluoxymesterone-induced gynaecomastia in a patient with childhood aplastic anaemia. BMJ Case Rep 2015. PMID 25948845